Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

R. Seban,Laura Mezquita,Arnaud Berenbaum,Laurent Dercle,Angela Botticella,Cecile Le Pechoux,Caroline Caramella,Eric W. Deutsch,Serena Grimaldi,J. Adam,Samy Ammari,David Planchard,Sophie Leboulleux,Benjamin Besse

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

2019

R. Seban
Laura Mezquita
Arnaud Berenbaum
Laurent Dercle
Angela Botticella
Cecile Le Pechoux
Caroline Caramella
Eric W. Deutsch
Serena Grimaldi
J. Adam
Samy Ammari
David Planchard
Sophie Leboulleux
Benjamin Besse

Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).

Keywords:

Internal medicine
Oncology
PET-CT
Biomarker (medicine)
Radiology
Medicine
Immune checkpoint
non small cell
fdg pet ct
in patient
immune checkpoint inhibitors
tumor burden

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations